Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System
June 18, 2018 08:45 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce the first four cataract...
Aequus Provides First Quarter 2018 Financial and Corporate Highlights
May 31, 2018 08:45 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, May 31, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018
May 16, 2018 08:45 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce it will be formally launching...
Aequus Receives Positive FDA Regulatory Guidance for Anti-Nausea Patch
May 03, 2018 08:45 ET
|
Aequus Pharmaceuticals
Key Highlights FDA has confirmed that an abbreviated 505(b)(2) regulatory pathway would be appropriate for the submission of AQS1303, Aequus’ long-acting anti-nausea patch for nausea and vomiting...
Aequus Provides Fourth Quarter and Fiscal 2017 Financial Highlights, Third Consecutive Quarter of Revenue Growth
April 27, 2018 09:30 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, April 27, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 2, 2018
April 26, 2018 12:00 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, April 26, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus and Camargo Complete Pre-Investigational New Drug Submission with FDA for Transdermal Anti-Nausea Program
April 17, 2018 08:45 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio
April 12, 2018 08:45 ET
|
Aequus Pharmaceuticals
VANCOUVER, B.C., April 12, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), is pleased to announce it has entered into a commercial...
Aequus Expands Market in Quebec for Tacrolimus IR
March 19, 2018 08:45 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, March 19, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), announced today that it has been awarded a...
FDA Confirms Date to Providing Regulatory Guidance for Aequus’ Anti-Nausea Patch
March 07, 2018 08:45 ET
|
Aequus Pharmaceuticals
VANCOUVER, British Columbia, March 07, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...